


## 1. PRODUCT AND COMPANY INFORMATION

**Distributed By:** WG Critical Care, LLC.  
120 Route 17 North  
Suite 115  
Paramus, NJ 07652 USA

**Product Name:** **Cefazolin for Injection, USP**

**Common / Trade Name:** Cefazolin for Injection, USP

**Structure:**



**Chemical Name:** (1) 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-8-oxo-7-[[[(1H-tetrazol-1-yl)acetyl]amino]-, monosodium salt (6R-trans)-; (2) Monosodium (6R,7R)-3-[[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (3) 3-[[[5-Methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-7-[2-(1H-tetrazol-1-yl)acetamido]-3-cephem-4-carboxylate

**Molecular Formula:** C<sub>14</sub>H<sub>13</sub>N<sub>8</sub>NaO<sub>4</sub>S<sub>3</sub>  
**UNII Code:** UNII-P380M0454Z  
**CAS Number:** 27164-46-1  
**Chemical Family:** Antibacterial (systemic)  
**Product Use:** Pharmaceutical  
**Product Type:** Prescription Drug

**Container Information:** Vials

WG Critical Care, LLC.

Cefazolin for Injection, USP	Safety Data Sheet (SDS)	
Version: 2.1	Issue Date: 30 July 2014	Page 1 of 6



**1. PRODUCT AND COMPANY INFORMATION (CONT.)**

**General Phone Number:** +1-847-549-3200  
**Customer Service Phone Number:** +1-888-493-0861  
**Emergency Phone Number:** +1-866-562-4708 (Prosar)

**2. HAZARDS IDENTIFICATION**

**PRIMARY PHYSICAL AND HEALTH HAZARDS:** May cause irritation to eyes, skin, and respiratory tract. Product may cause allergic reaction if inhaled or absorbed through the skin.

**ROUTES OF ENTRY:** Eyes, skin, inhalation.

**SIGNS & SYMPTOMS OF EXPOSURE:** Exposure can cause dilation of the blood vessels and an increase in contraction of some smooth muscles.

**CHEMICAL LISTED AS CARCINOGEN:** NTP: NO IARC: NO OSHA: NO

**3. COMPOSITION / INFORMATION ON INGREDIENTS**

<u>Ingredient</u>	<u>Weight %</u>	<u>CAS No.</u>
Cefazolin Sodium	100	27164-46-1

**4. FIRST AID MEASURES**

**EYE EXPOSURE:** Flush eyes with water for 10-20 minutes. Seek medical attention.  
**SKIN EXPOSURE:** Remove contaminated clothing wash skin for 15-20 minutes with soap and water. Seek medical attention.  
**INGESTION:** Do NOT induce vomiting. Flush mouth with water and seek medical attention immediately.  
**INHALATION:** If there is breathing difficulty, remove from exposure and administer oxygen. See medical attention immediately.  
**NOTE TO PHYSICIAN:** See patient package insert in shipping carton for complete information.

WG Critical Care, LLC.

Cefazolin for Injection, USP	Safety Data Sheet (SDS)	
Version: 2.1	Issue Date: 30 July 2014	Page 2 of 6



## 5. FIRE FIGHTING MEASURES

<b>FLASH POINT:</b>	Not established
<b>AUTO-IGNITION TEMPERATURE:</b>	Not established
<b>FLAMMABLE LIMITS IN AIR:</b>	Not established
<b>FLAMMABLE LIMITS:</b>	Not established
<b>EXTINGUISHING MEDIA:</b>	Water, dry chemical or foam.
<b>UNUSUAL FIRE / EXPLOSION HAZARDS:</b>	Not determined

## 6. ACCIDENTAL RELEASE MEASURE

<b>SPILL:</b>	Contain and collect spillage and place in container for disposal according to local regulations (See Section 13). Wipe surface area clean with soap and water. Avoid contact with strong oxidizing agents.
<b>RELEASE TO AIR:</b>	Prevent release to environment. If aerosolized reduce exposure by ventilating area.
<b>RELEASE TO WATER:</b>	Refer to local water authority. Drain disposal is not recommended; refer to local, state, and federal disposal guidelines.

## 7. HANDLING AND STORAGE

<b>GENERAL HANDLING:</b>	When handling pharmaceutical products, avoid all contact and inhalation of dust, fumes, mist, and/or vapors associated with the product. Keep away from sources of ignition.
<b>STORAGE CONDITIONS:</b>	Keep containers tightly closed in a cool, well-ventilated place. Store at room temperature between 20°C and 25°C (68°F and 77°F).

WG Critical Care, LLC.

Cefazolin for Injection, USP	Safety Data Sheet (SDS)	
Version: 2.1	Issue Date: 30 July 2014	Page 3 of 6



**8. EXPOSURE CONTROLS / PERSONAL PROTECTION**

**RESPIRATORY PROTECTION:** If aerosols are generated, a disposable dust/mist respirator (N95) may be used. Personnel wearing respirators should be fit tested and approved for respirator use under the OSHA Respiratory Protection Standard 29 CFR 1910.134.

**EYE PROTECTION:** Chemical goggles and/or face shield. Safety glasses are always required.

**VENTILATION:** Laboratory fume hood or local exhaust ventilation.

**SKIN PROTECTION:** Work uniform or laboratory coat.

**OTHER PROTECTIVE EQUIPMENT:** Protective Latex or Nitrile gloves

**ADDITIONAL EXPOSURE PRECAUTIONS:** In production settings, airline-supplied, hood-type respirators are preferred. Shower and change clothing if skin contact occurs.

**9. PHYSICAL AND CHEMICAL PROPERTIES**

<b>PHYSICAL STATE:</b>	Solid -	<b>SPECIFIC GRAVITY:</b>	Equivalent to water
<b>APPEARANCE AND ODOR:</b>	White to off-white lyophilized powder	<b>EVAPORATION RATE:</b>	Equivalent to water
<b>BOILING POINT:</b>	Not determined	<b>MELTING POINT:</b>	198-200°C
<b>VAPOR PRESSURE:</b>	Not determined	<b>SOLUBILITY IN WATER:</b>	Soluble in water
<b>VAPOR DENSITY:</b>	Not determined	<b>pH:</b>	4.5-6.0

**10. STABILITY AND REACTIVITY**

**STABILITY:** Store in a cool and ventilated place at the temperature of 25°C ± 2°C. Avoid exposure to heat sources also localized.

**INCOMPATIBILITY : (MATERIALS TO AVOID)** Strong oxidizing agents

**HAZARDOUS POLYMERIZATION:** Will not occur

**HAZARDOUS DECOMPOSITION:** When heated to decomposition material, it emits toxic fumes of sulfur oxide gases (SOx), nitrogen oxides(NOx) and sodium oxide (Na<sub>2</sub>O)(6).

**CONDITIONS TO AVOID:** Protect from moisture. Avoid accumulation of electronstatic charge. Keep away from open flames, heat and direct lighting.

WG Critical Care, LLC.

Cefazolin for Injection, USP	Safety Data Sheet (SDS)	
Version: 2.1	Issue Date: 30 July 2014	Page 4 of 6



### 11. TOXICOLOGICAL INFORMATION

#### ACUTE TOXICITY

COMPONENT	TYPE	ROUTE	SPECIES	DOSAGE
Cefazolin Sodium	LD <sub>50</sub>	IV	Rat	2760mg/kg

### 12. ECOLOGICAL INFORMATION

Not established

### 13. DISPOSAL CONSIDERATIONS

**WASTE DISPOSAL:** Dispose of any cleanup materials and waste products according to all local, state, and federal laws and regulations.

### 14. TRANSPORT INFORMATION

#### REGULATORY ORGANIZATIONS:

**DOT:** Not Regulated

**ICAO / IATA:** Not Regulated

**IMO:** Not Regulated

### 15. REGULATORY INFORMATION

Below is selected regulatory information chosen primarily for possible WG Critical Care use. This section is not a complete analysis or reference to all applicable regulatory information. Please consider all applicable laws and regulations for your city / state / country.

#### US Regulations

TSCA – No

CERCLA-No

SARA 302 – No

SARA 313 – No

OSHA Substance Specific - No

WG Critical Care, LLC.

Cefazolin for Injection, USP	Safety Data Sheet (SDS)		
Version: 2.1	Issue Date: 30 July 2014	Page 5 of 6	



## 16. OTHER INFORMATION

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

WG Critical Care, LLC.

Cefazolin for Injection, USP	Safety Data Sheet (SDS)	
Version: 2.1	Issue Date: 30 July 2014	Page 6 of 6